Newbury Pharmaceuticals Résultats passés
Passé contrôle des critères 0/6
Newbury Pharmaceuticals's earnings have been declining at an average annual rate of -23%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 79.8% per year.
Informations clés
-23.0%
Taux de croissance des bénéfices
-12.3%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 30.5% |
| Taux de croissance des recettes | 79.8% |
| Rendement des fonds propres | -29.7% |
| Marge nette | -41.8% |
| Prochaine mise à jour des résultats | 11 Dec 2024 |
Mises à jour récentes des performances passées
Recent updates
Ventilation des recettes et des dépenses
Comment Newbury Pharmaceuticals gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Aug 24 | 37 | -15 | 29 | 0 |
| 31 May 24 | 19 | -22 | 27 | 0 |
| 29 Feb 24 | 23 | -17 | 24 | 0 |
| 30 Nov 23 | 21 | -17 | 23 | 0 |
| 31 Aug 23 | 10 | -19 | 21 | 0 |
| 31 May 23 | 12 | -19 | 20 | 0 |
| 28 Feb 23 | 7 | -18 | 18 | 0 |
| 30 Nov 22 | 6 | -17 | 16 | 0 |
| 31 Aug 22 | 6 | -15 | 15 | 0 |
| 31 May 22 | 3 | -13 | 13 | 0 |
| 28 Feb 22 | 3 | -12 | 11 | 0 |
| 30 Nov 21 | 3 | -10 | 9 | 0 |
| 31 Aug 21 | 3 | -6 | 6 | 0 |
Des revenus de qualité: NEWBRY is currently unprofitable.
Augmentation de la marge bénéficiaire: NEWBRY is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: Insufficient data to determine if NEWBRY's year-on-year earnings growth rate was positive over the past 5 years.
Accélération de la croissance: Unable to compare NEWBRY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: NEWBRY is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (4.5%).
Rendement des fonds propres
ROE élevé: NEWBRY has a negative Return on Equity (-29.67%), as it is currently unprofitable.